Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)

NCT04329949 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT04329949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04329949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)
Lead sponsor
Corcept Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2020
Completion date
March 25, 2022
Enrollment
43 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic ductal adenocarcinoma